Dr. Keith L Ligon, MD, PhD is an Associate Professor of Pathology at Harvard Medical School and Director of the DFCI Center for Patient Derived Models. His laboratory focuses on development of novel functional diagnostic assays to determine drug response in cancer cells and incorporation of these assays into human clinical trials and pathology practice to advance personalized medicine for patients. He has expertise in patient derived xenografts, cell lines, and acute cell models research. He has specific scientific and clinical expertise in neurooncology and is a Board Certified Neuropatholgoist and Chief of Neuropathology at the Brigham and Women’s Hospital and Dana-Farber Cancer Institute. He is a Co-Founder and Scientific Advisor to Travera which is working to develop single cell mass biomarkers as functional diagnostics in cancer.